Sleep disordered breathing and metabolic comorbidities across sex and menopausal status in East Asians: the Nagahama Study

Takeshi Matsumoto, Kimihiko Murase, Yasuharu Tabara, Takuma Minami, Osamu Kanai, Hirofumi Takeyama, Naomi Takahashi, Satoshi Hamada, Kiminobu Tanizawa, Tomoko Wakamura, Naoko Komenami, Kazuya Setoh, Takahisa Kawaguchi, Takanobu Tsutsumi, Satoshi Morita, Yoshimitsu Takahashi, Takeo Nakayama, Toyohiro Hirai, Fumihiko Matsuda and Kazuo Chin

Affiliations: 1Dept of Respiratory Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan. 2Dept of Respiratory Medicine, Saiseikai-Noe Hospital, Osaka, Japan. 3Dept of Respiratory Care and Sleep Control Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan. 4Center for Genomic Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan. 5Dept of Advanced Medicine for Respiratory Failure, Kyoto University Graduate School of Medicine, Kyoto, Japan. 6Nursing Science, Human Health Sciences, Kyoto Women’s University, Kyoto, Japan. 7Dept of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan. 8Dept of Health Informatics, School of Public Health, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Correspondence: Kazuo Chin, Dept of Respiratory Care and Sleep Control Medicine, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan. E-mail. chinkuhp.kyoto-u.ac.jp

Metabolic comorbidities (hypertension, diabetes, dyslipidaemia, metabolic syndrome) contribute to SDB regardless of obesity grade. We should recognise the extremely high prevalence of moderate–severe SDB in patients with obesity and metabolic comorbidities.


This single-page version can be shared freely online.

ABSTRACT It is well known that the prevalence of sleep disordered breathing (SDB) is increased in patients with obesity or metabolic comorbidities. However, the way in which the prevalence of SDB increases in relation to comorbidities according to the severity of obesity remains unclear.

This cross-sectional study evaluated 7713 community participants using nocturnal oximetry ≥2 nights. SDB was assessed by the 3% oxygen desaturation index corrected for sleep duration obtained by wrist actigraphy (acti-ODI3%). SDB severity was defined by acti-ODI3%. Obesity was defined as body mass index ≥25 kg·m⁻².

The prevalence of SDB was 41.0% (95% CI 39.9–42.1%), 46.9% (45.8–48.0%), 10.1% (9.5–10.8%) and 2.0% (1.7–2.3%) in normal, mild, moderate and severe SDB, respectively, with notable sex differences evident (males>post-menopausal females>premenopausal females). Comorbidities such as hypertension, diabetes and metabolic syndrome were independently associated with the prevalence of moderate-to-severe SDB, and coincidence of any one of these with obesity was associated with a higher probability of...
moderate-to-severe SDB (hypertension OR 8.2, 95% CI 6.6–10.2; diabetes OR 7.8, 95% CI 5.6–10.9; metabolic syndrome OR 6.7, 95% CI 5.2–8.6). Dyslipidaemia in addition to obesity was not additively associated with the prevalence of moderate-to-severe SDB. The number of antihypertensive drugs was associated with SDB (p for trend <0.001). Proportion of a high cumulative percentage of sleep time with oxygen saturation measured by pulse oximetry <90% increased, even among moderate-to-severe SDB with increases in obesity.

Metabolic comorbidities contribute to SDB regardless of the degree of obesity. We should recognise the extremely high prevalence of moderate-to-severe SDB in patients with obesity and metabolic comorbidities.